Knockdown of miR-384-3p Protects Against Myocardial Ischemia-Reperfusion Injury in Rats Through Targeting HSP70
DOI:
https://doi.org/10.1532/hsf.3449Keywords:
MiR-384-3p, HSP70, Ischemia-reperfusion, Myocardial infarction, apoptosisAbstract
Background: Myocardial infarction (MI) and heart failure remain critical states of heart disease with high mortality. Previous studies have indicated that miRNA has cardioprotective effects and can resist myocardial ischemia–reperfusion (I/R) injury. However, the role of mir-384-3p in MI has not been reported, and whether this miRNA can regulate the apoptosis of cardiomyocytes needs to be verified.
Methods: The effect of hypoxia–reperfusion (H/R) on cardiomyocyte activity was detected using MTT assay. MiR-384-3p was knocked down or overexpressed in cardiomyocytes H/R models by pretreatment with miR-384-3p mimic or inhibitor to verify the function of miR-384-3p in H/R. Circulating levels of miR-384-3p was detected by quantitative realtime PCR, and protein expression was detected by western blotting. TUNEL staining and flow cytometry demonstrated a high degree of myocardium apoptosis after H/R induction. Dual-Luciferase Reporter Assay detected dynamic expression of miR-384-3p and HSP70. The infarction size of I/R rats was detected by 2,3,5-triphenyltetrazolium chloride (TTC) staining.
Results: MiR-384-3p was closely related to cardiomyocyte activity in H/R progression. Increased expression of mir-384-3p can promote the production of cleaved caspase-3 and cleaved PARP, thereby regulating cardiomyocyte apoptosis. HSP70 was a target of miR-384-3p and HSP70 silencing aggravated H/R-induced cardiomyocyte dysfunction. In an animal model, the expression level of HSP70 is regulated by miR-384-3p, and miR-384-3p inhibition remarkably reduced I/R-induced MI in rats.
Conclusion: In conclusion, the present report identified that HSP70 was a potential target of miR-384-3p, and miR-384-3p inhibition remarkably reduced I/R-induced MI in rats. Therefore, this study provides a novel therapeutic approach for the treatment of MI from bench to clinic.
References
Bari K, Petrik J, Rumora L. 2003. Biochemistry of apoptotic cell death. Acta pharm 53:151-164.
Bartel D. 2018. Metazoan MicroRNAs. Cell 173:20-51.
Becker J, Craig E. 1994. Heat-shock proteins as molecular chaperones. European journal of biochemistry 219:11-23.
Bhaskaran M, Mohan M. 2014. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Veterinary pathology 51:759-774.
Borosch S, Dahmen E, Beckers C, Stoppe C, Buhl EM, Denecke B, et al. 2017. Characterization of extracellular vesicles derived from cardiac cells in an in vitro model of preconditioning. Journal of extracellular vesicles 6:1390391.
Connarn J, Assimon V, Reed R, Tse E, Southworth D, Zuiderweg E, et al. 2014. The molecular chaperone Hsp70 activates protein phosphatase 5 (PP5) by binding the tetratricopeptide repeat (TPR) domain. The Journal of biological chemistry 289:2908-2917.
de Lucia C, Komici K, Borghetti G, Femminella GD, Bencivenga L, Cannavo A, et al. 2017. microRNA in cardiovascular aging and age-related cardiovascular diseases. Frontiers in medicine 4:74.
Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, et al. 2009. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. The Journal of biological chemistry 284:29514-29525.
Heusch G, Boengler K, Schulz R. 2008. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915-1919.
Hullinger T, Montgomery R, Seto A, Dickinson B, Semus H, Lynch J, et al. 2012. Inhibition of miR-15 protects against cardiac ischemic injury. Circulation research 110:71-81.
Ke J, Yao Y-l, Zheng J, Wang P, Liu Y-h, Ma J, et al. 2015. Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326. Oncotarget 6:21934.
Kim EN, Kim CJ, Kim SR, Song J-A, Choe H, Kim K-B, et al. 2019. High serum CRP influences myocardial miRNA profiles in ischemia-reperfusion injury of rat heart. PLoS One 14:e0216610.
Kupatt C, Hinkel R, Pfosser A, El-Aouni C, Wuchrer A, Fritz A, et al. 2010. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. Journal of the American College of Cardiology 56:414-422.
Liu X, Zhang C, Zhang C, Li J, Guo W, Yan D, et al. 2016. Heat shock protein 70 inhibits cardiomyocyte necroptosis through repressing autophagy in myocardial ischemia/reperfusion injury. In vitro cellular & developmental biology Animal 52:690-698.
Maneechote C, Palee S, Kerdphoo S, Jaiwongkam T, Chattipakorn SC, Chattipakorn N. 2018. Differential temporal inhibition of mitochondrial fission by Mdivi-1 exerts effective cardioprotection in cardiac ischemia/reperfusion injury. Clinical Science 132:1669-1683.
Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M, et al. 2016. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation 133:447-454.
Peng L, Chun-guang Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, et al. 2014. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagnostic pathology 9:89.
Peng W, Zhang Y, Zheng M, Cheng H, Zhu W, Cao C, et al. 2010. Cardioprotection by CaMKII-deltaB is mediated by phosphorylation of heat shock factor 1 and subsequent expression of inducible heat shock protein 70. Circulation research 106:102-110.
Pinchi E, Frati P, Aromatario M, Cipolloni L, Fabbri M, La Russa R, et al. 2019. miR-1, miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction. Journal of cellular and molecular medicine 23:6005-6016.
Ribeil J-A, Zermati Y, Vandekerckhove J, Cathelin S, Kersual J, Dussiot M, et al. 2007. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 445:102-105.
Rzeszutek I, Singh A. 2020. Small RNAs, Big Diseases. International journal of molecular sciences 21:
Samanta S, Balasubramanian S, Rajasingh S, Patel U, Dhanasekaran A, Dawn B, et al. 2016. MicroRNA: a new therapeutic strategy for cardiovascular diseases. Trends in cardiovascular medicine 26:407-419.
Song Y, Zhong C, Wang X. 2019. Heat shock protein 70: A promising therapeutic target for myocardial ischemia-reperfusion injury. Journal of cellular physiology 234:1190-1207.
Tan H, Qi J, Fan B, Zhang J, Su F, Wang H. 2018. MicroRNA-24-3p Attenuates Myocardial Ischemia/Reperfusion Injury by Suppressing RIPK1 Expression in Mice. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 51:46-62.
Tang X, Sato H, Tiwari S, Dawn B, Bi Q, Li Q, et al. 2006. Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 min. American journal of physiology Heart and circulatory physiology 291:H2308-2317.
Vainio L, Szabó Z, Lin R, Ulvila J, Yrjölä R, Alakoski T, et al. 2019. Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction. JACC Basic to translational science 4:83-94.
Wang X, Ha T, Hu Y, Lu C, Liu L, Zhang X, et al. 2016. MicroRNA-214 protects against hypoxia/reoxygenation induced cell damage and myocardial ischemia/reperfusion injury via suppression of PTEN and Bim1 expression. Oncotarget 7:86926-86936.
Wang Y, Chen Y, Liu S, Ye Y, Jiao H, Wang S, et al. 2016. MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Oncotarget 7:84826-84838.
Xia F, Sun J, Jiang Y, Li C. 2018. MicroRNA-384-3p inhibits retinal neovascularization through targeting hexokinase 2 in mice with diabetic retinopathy. Journal of cellular physiology 234:721-730.
Xia P, Liu Y, Cheng Z. 2016. Signaling Pathways in Cardiac Myocyte Apoptosis. BioMed research international 2016:9583268.
Xiao J, Shen B, Li J, Lv D, Zhao Y, Wang F, et al. 2014. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. International journal of clinical and experimental medicine 7:136.
Yu N, Kakunda M, Pham V, Lill J, Du P, Wongchenko M, et al. 2015. HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin. Molecular and cellular biology 35:1390-1400.
Zhang L, Chen X, Su T, Li H, Huang Q, Wu D, et al. 2015. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. Journal of thoracic disease 7:303-308.
Zhu Z, Zhu J, Zhao X, Yang K, Lu L, Zhang F, et al. 2015. All-trans retinoic acid ameliorates myocardial ischemia/reperfusion injury by reducing cardiomyocyte apoptosis. PLoS One 10:e0133414.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
